🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. TAK-816+ DPT-TAKEDA

    Takeda

    Immunization

    phase 3 mab completed

    1 trial

  2. TAK-861

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

  3. TAK-861

    Takeda

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  4. TAK-861, TAK-861 placebo (same excipients as TAK-861)

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  5. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  6. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  7. TAK-881

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 mab active

    1 trial

  8. TAK-881

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab active

    2 trials

  9. TAK-881

    Baxalta Innovations GmbH

    Primary Immunodeficiency Diseases

    phase 3 small molecule active

    1 trial

  10. TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use

    Takeda

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  11. TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  12. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Shanghai Reinovax Biologics Co.,LTD

    Breast cancer

    phase 3 small molecule active

    1 trial

  13. TAP-144-SR(6M)

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  14. TAP-144-SR(6M)

    Takeda

    Premenopausal Breast Cancer

    phase 3 small molecule completed

    1 trial

  15. TARGET protocol EN 1.5 kcal/mL

    Zealand Pharma A/S

    Critical Illness

    phase 3 other completed

    1 trial

  16. TASIMELTEON, HETLIOZ 20 mg hard capsules

    Lacuna Pharma Pty Ltd

    Non-24 Hour Sleep-Wake Disorder

    phase 3 small molecule active

    1 trial

  17. TAXOL 6 mg/ml, concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  18. TD-1473 Dose A

    Theravance Biopharma Ireland Umited

    Ulcerative Colitis (UC)

    phase 3 small molecule terminated

    2 trials

  19. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. TEMOZOLOMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, saline solution for infusion

    Novo Nordisk A/S

    Newly diagnosed Glioblastoma

    phase 3 small molecule active

    1 trial

  21. TENOFOVIR DISOPROXIL , ENTECAVIR , VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR ALAFENAMIDE

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  22. TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil

    Merck Sharp and Dohme

    HIV-1 prevention

    phase 3 small molecule active

    1 trial

  23. TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection

    Gilead Sciences Pty Limited

    Human Immunodeficiency Virus (HIV-1) infection

    phase 3 small molecule active

    1 trial

  24. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources